04:20 , Dec 8, 2017 |  BC Week In Review  |  Financial News

OrbiMed , Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round on Dec. 4 led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The...
23:06 , Dec 4, 2017 |  BC Extra  |  Financial News

OrbiMed, Thiel lead ChemomAb's $10M series B

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The company previously raised...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Antitope, ChemomAb deal

The companies partnered to generate humanized mAbs devoid of T cell epitopes to treat inflammatory diseases using Antitope's Composite Human Antibody technology. Antitope said the deal combines its humanization and immunogenicity technologies with ChemomAb's therapeutic...
07:00 , Jun 25, 2009 |  BC Innovations  |  Targets & Mechanisms

Seeing CNV sooner

New research by a multinational team suggests that noninvasive imaging of CC chemokine receptor 3 could help detect wet age-related macular degeneration before retinal damage occurs. 1 This would allow earlier therapeutic intervention, which is...
07:00 , Jun 18, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Age-related macular degeneration (AMD) CC chemokine receptor 3 (CCR3); eotaxin-1 (CCL11); eotaxin-2 (CCL24); eotaxin-3 (CCL26) Studies in human tissues and in mice suggest...